Deere & Company Surpasses Q2 Expectations, Foot Locker Falls Short, and Intercept Pharmaceuticals Stock Halted Amid FDA Review
- May 19th, 2023
- 643 views
Deere & Company (NYSE: DE) has released its second-quarter fiscal 2023 earnings per share (EPS) report, surpassing consensus expectations. The company reported an EPS of $9.65, exceeding the consensus estimate of $8.59.
John C. May, the chairman and chief executive officer of Deere, expressed satisfaction with the outstanding second-quarter results. He noted that Deere continues to benefit from favorable market conditions and an improving operating environment.
In pre-market trading, $DE is currently valued at $385.00, experiencing a significant increase of $14.48 (+3.91%).
On the other hand, Foot Locker, Inc. (NYSE: FL) has released its first-quarter 2023 earnings report, which fell short of consensus expectations. The company reported an EPS of $0.70, lower than the consensus estimate of $0.81, and a decline in comparable-store sales by 9.1%, primarily attributed to macroeconomic headwinds -including lower income tax refunds in the United States-.
In pre-market trading, $FL is currently valued at $31.89, showing a significant decrease of $9.63 (-23.19%).
In other news, NASDAQ has halted trading of Intercept Pharmaceuticals, Inc.'s (Nasdaq: ICPT) common stock. The reason behind this halt is the ongoing meeting of the U.S. Food and Drug Administration's (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC), which is currently reviewing the use of obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).
Please note that the stock prices and pre-market movements mentioned here are for illustrative purposes and may not reflect the current market conditions at the time of reading.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025




Member Login